In the DUO and DYNAMO trials, duvelisib improved clinical responses in patients with R/R CLL/SLL and FL, respectively.
The combination of rituximab and the BCL2 inhibitor venetoclax significantly lengthened PFS among CLL patients in the phase III MURANO trial.
Antibiotics administered within 30 days of starting immunotherapy reduced both PFS and OS for patients with advanced RCC and NSCLC.
mXELIRI could be practice-changing by providing an alternative to irinotecan-based regimens for some patients, but may not work in non-Asian populations.
A large prospective analysis of data from the UK Women’s Cohort Study found an association between red meat consumption and distal colon disease risk.
Three year OS was significantly worse compared with the general population, with a persistent risk for relapse.
CR was 36% in the total neoadjuvant therapy cohort vs 21% in the cohort that received chemoradiotherapy with adjuvant chemotherapy.
A large prospective analysis of three large cohorts found a positive link between risk for myeloma and cumulative average young adult and adult BMI.
First-line combination therapy with the PD-L1 inhibitor avelumab and the VEGFR TKI axitinib yielded antitumor activity in previously untreated RCC.
Compared with sorafenib, tivozanib significantly improved PFS and OS, and yielded significantly higher ORRs, a crossover analysis of TIVO-1 found.